Long intergenic non‐coding RNA 511 correlates with improved prognosis, and hinders osteosarcoma progression both in vitro and in vivo
Background This study aimed to investigate the correlation of long intergenic non‐coding RNA 511 (LINC00511) with clinicopathological characteristics and overall survival (OS) in osteosarcoma patients and to explore its function in osteosarcoma in vitro and in vivo. Methods Tumor tissues and adjacen...
Gespeichert in:
| Veröffentlicht in: | Journal of clinical laboratory analysis 2020-05, Vol.34 (5), p.e23164-n/a |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | n/a |
|---|---|
| container_issue | 5 |
| container_start_page | e23164 |
| container_title | Journal of clinical laboratory analysis |
| container_volume | 34 |
| creator | Qiao, Suchi Qi, Ke Liu, Chang Xu, Changli Ma, Jun Xu, Xinmin Li, Cheng Wang, Zhiwei |
| description | Background
This study aimed to investigate the correlation of long intergenic non‐coding RNA 511 (LINC00511) with clinicopathological characteristics and overall survival (OS) in osteosarcoma patients and to explore its function in osteosarcoma in vitro and in vivo.
Methods
Tumor tissues and adjacent tissues from 45 osteosarcoma patients were acquired, and LINC00511 expression was detected. In vitro, LINC00511 expression was detected in osteosarcoma cell lines and osteoblast cell line. LINC00511 overexpression‐treated (OE‐LINC00511) and nonsense overexpression‐treated (OE‐control) MG‐63 and Saos‐2 cells were cultured, followed by the assessment of cell proliferation, apoptosis, migration, and invasion. In vivo, tumor weight and volume were measured in OE‐LINC00511 and OE‐control xenografted mice.
Results
LINC00511 expression was decreased in tumor tissues compared with adjacent tissues (P |
| doi_str_mv | 10.1002/jcla.23164 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7246352</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2332082187</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4484-e27b1647a787d92ba99b0ac3d6db4275b11ca560d1a483552895cbff206115cc3</originalsourceid><addsrcrecordid>eNp9kc9uEzEQhy1ERUPhwgMgS1wQYov_rNfeS6UoAtoqAgnB2fLaTuJo1xPsTareuHHlGXkSnKRUwIHTyJ5vPs3oh9AzSs4pIezN2vbmnHHa1A_QhJJWVUwx8RBNiFKyUoTyU_Q45zUhRLW0eYROOVUtF1JO0Pc5xCUOcfRp6WOwOEL8-e2HBRfK_6cPUywoxRZS8r0ZfcY3YVzhMGwS7LzDpSwj5JBfYxMdXoXofMoY8ughm2RhMAcm-ZwDRNzBfjriXRgTHEYOjx08QScL02f_9K6eoS_v3n6eXVbzj--vZtN5Zeta1ZVnsit3SiOVdC3rTNt2xFjuGtfVTIqOUmtEQxw1teJCMNUK2y0WjDSUCmv5Gbo4ejfbbvDO-jgm0-tNCoNJtxpM0H93YljpJey0ZHXDBSuCl3eCBF-3Po96CNn6vjfRwzZrxjkjilElC_riH3QN2xTLeZrVpGGi7LQXvjpSNkHOyS_ul6FE7_PV-3z1Id8CP_9z_Xv0d6AFoEfgJvT-9j8qfT2bT4_SX9ldsyU</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2406256112</pqid></control><display><type>article</type><title>Long intergenic non‐coding RNA 511 correlates with improved prognosis, and hinders osteosarcoma progression both in vitro and in vivo</title><source>MEDLINE</source><source>Wiley Online Library Open Access</source><source>DOAJ Directory of Open Access Journals</source><source>Wiley Online Library Journals Frontfile Complete</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Qiao, Suchi ; Qi, Ke ; Liu, Chang ; Xu, Changli ; Ma, Jun ; Xu, Xinmin ; Li, Cheng ; Wang, Zhiwei</creator><creatorcontrib>Qiao, Suchi ; Qi, Ke ; Liu, Chang ; Xu, Changli ; Ma, Jun ; Xu, Xinmin ; Li, Cheng ; Wang, Zhiwei</creatorcontrib><description><![CDATA[Background
This study aimed to investigate the correlation of long intergenic non‐coding RNA 511 (LINC00511) with clinicopathological characteristics and overall survival (OS) in osteosarcoma patients and to explore its function in osteosarcoma in vitro and in vivo.
Methods
Tumor tissues and adjacent tissues from 45 osteosarcoma patients were acquired, and LINC00511 expression was detected. In vitro, LINC00511 expression was detected in osteosarcoma cell lines and osteoblast cell line. LINC00511 overexpression‐treated (OE‐LINC00511) and nonsense overexpression‐treated (OE‐control) MG‐63 and Saos‐2 cells were cultured, followed by the assessment of cell proliferation, apoptosis, migration, and invasion. In vivo, tumor weight and volume were measured in OE‐LINC00511 and OE‐control xenografted mice.
Results
LINC00511 expression was decreased in tumor tissues compared with adjacent tissues (P < .001), and its high expression correlated with increased tumor cell necrosis rate to neoadjuvant chemotherapy (P = .025) and prolonged OS (P = .010). In vitro, LINC00511 expression was decreased in osteosarcoma cell lines (including MG‐63, U‐2OS, Saos‐2, and HOS) compared with osteoblast cell line (All P < .001). Cell proliferation was decreased at 48 hours (Both P < .01) and 72 hours (Both P < .001) (in MG‐63 and Saos‐2 cells); cell apoptosis was increased (P < .05) (in Saos‐2 cells); cell migration and invasion were decreased (All P < .01) (in MG‐63 cells and Saos‐2 cells) in OE‐LINC00511 compared with OE‐control. In vivo, tumor volume was reduced at week 4 (P < .001), week 5 (P < .001), week 6 (P < .001) in OE‐LINC00511 compared with OE‐control. Tumor weight was declined in OE‐LINC00511 than OE‐control (P < .001).
Conclusions
LINC00511 acts as a potential biomarker and therapeutic option for osteosarcoma.]]></description><identifier>ISSN: 0887-8013</identifier><identifier>EISSN: 1098-2825</identifier><identifier>DOI: 10.1002/jcla.23164</identifier><identifier>PMID: 31893577</identifier><language>eng</language><publisher>United States: John Wiley & Sons, Inc</publisher><subject>Adolescent ; Adult ; Animals ; Apoptosis ; Apoptosis - genetics ; Biopsy ; Bone cancer ; Bone Neoplasms - genetics ; Bone Neoplasms - mortality ; Bone Neoplasms - pathology ; Bone Neoplasms - therapy ; Cell Line, Tumor ; Cell migration ; Cell motility ; Cell proliferation ; cell survival ; Chemotherapy ; Child ; Female ; Gene Expression Regulation, Neoplastic ; Hospitals ; Humans ; Kaplan-Meier Estimate ; long intergenic non‐coding RNA 511 ; Male ; Medical prognosis ; Metastasis ; Mice, Inbred BALB C ; Neoadjuvant Therapy ; Non-coding RNA ; Osteosarcoma ; Osteosarcoma - genetics ; Osteosarcoma - mortality ; Osteosarcoma - pathology ; Osteosarcoma - therapy ; Prognosis ; Ribonucleic acid ; RNA ; RNA, Long Noncoding - genetics ; Sarcoma ; Surgery ; tumor progression ; Xenograft Model Antitumor Assays ; Xenografts ; Young Adult</subject><ispartof>Journal of clinical laboratory analysis, 2020-05, Vol.34 (5), p.e23164-n/a</ispartof><rights>2019 The Authors. Published by Wiley Periodicals, Inc.</rights><rights>2019 The Authors. Journal of Clinical Laboratory Analysis Published by Wiley Periodicals, Inc.</rights><rights>2020. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4484-e27b1647a787d92ba99b0ac3d6db4275b11ca560d1a483552895cbff206115cc3</citedby><cites>FETCH-LOGICAL-c4484-e27b1647a787d92ba99b0ac3d6db4275b11ca560d1a483552895cbff206115cc3</cites><orcidid>0000-0003-2039-2948</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7246352/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7246352/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,1411,11541,27901,27902,45550,45551,46027,46451,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31893577$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Qiao, Suchi</creatorcontrib><creatorcontrib>Qi, Ke</creatorcontrib><creatorcontrib>Liu, Chang</creatorcontrib><creatorcontrib>Xu, Changli</creatorcontrib><creatorcontrib>Ma, Jun</creatorcontrib><creatorcontrib>Xu, Xinmin</creatorcontrib><creatorcontrib>Li, Cheng</creatorcontrib><creatorcontrib>Wang, Zhiwei</creatorcontrib><title>Long intergenic non‐coding RNA 511 correlates with improved prognosis, and hinders osteosarcoma progression both in vitro and in vivo</title><title>Journal of clinical laboratory analysis</title><addtitle>J Clin Lab Anal</addtitle><description><![CDATA[Background
This study aimed to investigate the correlation of long intergenic non‐coding RNA 511 (LINC00511) with clinicopathological characteristics and overall survival (OS) in osteosarcoma patients and to explore its function in osteosarcoma in vitro and in vivo.
Methods
Tumor tissues and adjacent tissues from 45 osteosarcoma patients were acquired, and LINC00511 expression was detected. In vitro, LINC00511 expression was detected in osteosarcoma cell lines and osteoblast cell line. LINC00511 overexpression‐treated (OE‐LINC00511) and nonsense overexpression‐treated (OE‐control) MG‐63 and Saos‐2 cells were cultured, followed by the assessment of cell proliferation, apoptosis, migration, and invasion. In vivo, tumor weight and volume were measured in OE‐LINC00511 and OE‐control xenografted mice.
Results
LINC00511 expression was decreased in tumor tissues compared with adjacent tissues (P < .001), and its high expression correlated with increased tumor cell necrosis rate to neoadjuvant chemotherapy (P = .025) and prolonged OS (P = .010). In vitro, LINC00511 expression was decreased in osteosarcoma cell lines (including MG‐63, U‐2OS, Saos‐2, and HOS) compared with osteoblast cell line (All P < .001). Cell proliferation was decreased at 48 hours (Both P < .01) and 72 hours (Both P < .001) (in MG‐63 and Saos‐2 cells); cell apoptosis was increased (P < .05) (in Saos‐2 cells); cell migration and invasion were decreased (All P < .01) (in MG‐63 cells and Saos‐2 cells) in OE‐LINC00511 compared with OE‐control. In vivo, tumor volume was reduced at week 4 (P < .001), week 5 (P < .001), week 6 (P < .001) in OE‐LINC00511 compared with OE‐control. Tumor weight was declined in OE‐LINC00511 than OE‐control (P < .001).
Conclusions
LINC00511 acts as a potential biomarker and therapeutic option for osteosarcoma.]]></description><subject>Adolescent</subject><subject>Adult</subject><subject>Animals</subject><subject>Apoptosis</subject><subject>Apoptosis - genetics</subject><subject>Biopsy</subject><subject>Bone cancer</subject><subject>Bone Neoplasms - genetics</subject><subject>Bone Neoplasms - mortality</subject><subject>Bone Neoplasms - pathology</subject><subject>Bone Neoplasms - therapy</subject><subject>Cell Line, Tumor</subject><subject>Cell migration</subject><subject>Cell motility</subject><subject>Cell proliferation</subject><subject>cell survival</subject><subject>Chemotherapy</subject><subject>Child</subject><subject>Female</subject><subject>Gene Expression Regulation, Neoplastic</subject><subject>Hospitals</subject><subject>Humans</subject><subject>Kaplan-Meier Estimate</subject><subject>long intergenic non‐coding RNA 511</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Metastasis</subject><subject>Mice, Inbred BALB C</subject><subject>Neoadjuvant Therapy</subject><subject>Non-coding RNA</subject><subject>Osteosarcoma</subject><subject>Osteosarcoma - genetics</subject><subject>Osteosarcoma - mortality</subject><subject>Osteosarcoma - pathology</subject><subject>Osteosarcoma - therapy</subject><subject>Prognosis</subject><subject>Ribonucleic acid</subject><subject>RNA</subject><subject>RNA, Long Noncoding - genetics</subject><subject>Sarcoma</subject><subject>Surgery</subject><subject>tumor progression</subject><subject>Xenograft Model Antitumor Assays</subject><subject>Xenografts</subject><subject>Young Adult</subject><issn>0887-8013</issn><issn>1098-2825</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9kc9uEzEQhy1ERUPhwgMgS1wQYov_rNfeS6UoAtoqAgnB2fLaTuJo1xPsTareuHHlGXkSnKRUwIHTyJ5vPs3oh9AzSs4pIezN2vbmnHHa1A_QhJJWVUwx8RBNiFKyUoTyU_Q45zUhRLW0eYROOVUtF1JO0Pc5xCUOcfRp6WOwOEL8-e2HBRfK_6cPUywoxRZS8r0ZfcY3YVzhMGwS7LzDpSwj5JBfYxMdXoXofMoY8ughm2RhMAcm-ZwDRNzBfjriXRgTHEYOjx08QScL02f_9K6eoS_v3n6eXVbzj--vZtN5Zeta1ZVnsit3SiOVdC3rTNt2xFjuGtfVTIqOUmtEQxw1teJCMNUK2y0WjDSUCmv5Gbo4ejfbbvDO-jgm0-tNCoNJtxpM0H93YljpJey0ZHXDBSuCl3eCBF-3Po96CNn6vjfRwzZrxjkjilElC_riH3QN2xTLeZrVpGGi7LQXvjpSNkHOyS_ul6FE7_PV-3z1Id8CP_9z_Xv0d6AFoEfgJvT-9j8qfT2bT4_SX9ldsyU</recordid><startdate>202005</startdate><enddate>202005</enddate><creator>Qiao, Suchi</creator><creator>Qi, Ke</creator><creator>Liu, Chang</creator><creator>Xu, Changli</creator><creator>Ma, Jun</creator><creator>Xu, Xinmin</creator><creator>Li, Cheng</creator><creator>Wang, Zhiwei</creator><general>John Wiley & Sons, Inc</general><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-2039-2948</orcidid></search><sort><creationdate>202005</creationdate><title>Long intergenic non‐coding RNA 511 correlates with improved prognosis, and hinders osteosarcoma progression both in vitro and in vivo</title><author>Qiao, Suchi ; Qi, Ke ; Liu, Chang ; Xu, Changli ; Ma, Jun ; Xu, Xinmin ; Li, Cheng ; Wang, Zhiwei</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4484-e27b1647a787d92ba99b0ac3d6db4275b11ca560d1a483552895cbff206115cc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Animals</topic><topic>Apoptosis</topic><topic>Apoptosis - genetics</topic><topic>Biopsy</topic><topic>Bone cancer</topic><topic>Bone Neoplasms - genetics</topic><topic>Bone Neoplasms - mortality</topic><topic>Bone Neoplasms - pathology</topic><topic>Bone Neoplasms - therapy</topic><topic>Cell Line, Tumor</topic><topic>Cell migration</topic><topic>Cell motility</topic><topic>Cell proliferation</topic><topic>cell survival</topic><topic>Chemotherapy</topic><topic>Child</topic><topic>Female</topic><topic>Gene Expression Regulation, Neoplastic</topic><topic>Hospitals</topic><topic>Humans</topic><topic>Kaplan-Meier Estimate</topic><topic>long intergenic non‐coding RNA 511</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Metastasis</topic><topic>Mice, Inbred BALB C</topic><topic>Neoadjuvant Therapy</topic><topic>Non-coding RNA</topic><topic>Osteosarcoma</topic><topic>Osteosarcoma - genetics</topic><topic>Osteosarcoma - mortality</topic><topic>Osteosarcoma - pathology</topic><topic>Osteosarcoma - therapy</topic><topic>Prognosis</topic><topic>Ribonucleic acid</topic><topic>RNA</topic><topic>RNA, Long Noncoding - genetics</topic><topic>Sarcoma</topic><topic>Surgery</topic><topic>tumor progression</topic><topic>Xenograft Model Antitumor Assays</topic><topic>Xenografts</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Qiao, Suchi</creatorcontrib><creatorcontrib>Qi, Ke</creatorcontrib><creatorcontrib>Liu, Chang</creatorcontrib><creatorcontrib>Xu, Changli</creatorcontrib><creatorcontrib>Ma, Jun</creatorcontrib><creatorcontrib>Xu, Xinmin</creatorcontrib><creatorcontrib>Li, Cheng</creatorcontrib><creatorcontrib>Wang, Zhiwei</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Biological Science Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of clinical laboratory analysis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Qiao, Suchi</au><au>Qi, Ke</au><au>Liu, Chang</au><au>Xu, Changli</au><au>Ma, Jun</au><au>Xu, Xinmin</au><au>Li, Cheng</au><au>Wang, Zhiwei</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Long intergenic non‐coding RNA 511 correlates with improved prognosis, and hinders osteosarcoma progression both in vitro and in vivo</atitle><jtitle>Journal of clinical laboratory analysis</jtitle><addtitle>J Clin Lab Anal</addtitle><date>2020-05</date><risdate>2020</risdate><volume>34</volume><issue>5</issue><spage>e23164</spage><epage>n/a</epage><pages>e23164-n/a</pages><issn>0887-8013</issn><eissn>1098-2825</eissn><abstract><![CDATA[Background
This study aimed to investigate the correlation of long intergenic non‐coding RNA 511 (LINC00511) with clinicopathological characteristics and overall survival (OS) in osteosarcoma patients and to explore its function in osteosarcoma in vitro and in vivo.
Methods
Tumor tissues and adjacent tissues from 45 osteosarcoma patients were acquired, and LINC00511 expression was detected. In vitro, LINC00511 expression was detected in osteosarcoma cell lines and osteoblast cell line. LINC00511 overexpression‐treated (OE‐LINC00511) and nonsense overexpression‐treated (OE‐control) MG‐63 and Saos‐2 cells were cultured, followed by the assessment of cell proliferation, apoptosis, migration, and invasion. In vivo, tumor weight and volume were measured in OE‐LINC00511 and OE‐control xenografted mice.
Results
LINC00511 expression was decreased in tumor tissues compared with adjacent tissues (P < .001), and its high expression correlated with increased tumor cell necrosis rate to neoadjuvant chemotherapy (P = .025) and prolonged OS (P = .010). In vitro, LINC00511 expression was decreased in osteosarcoma cell lines (including MG‐63, U‐2OS, Saos‐2, and HOS) compared with osteoblast cell line (All P < .001). Cell proliferation was decreased at 48 hours (Both P < .01) and 72 hours (Both P < .001) (in MG‐63 and Saos‐2 cells); cell apoptosis was increased (P < .05) (in Saos‐2 cells); cell migration and invasion were decreased (All P < .01) (in MG‐63 cells and Saos‐2 cells) in OE‐LINC00511 compared with OE‐control. In vivo, tumor volume was reduced at week 4 (P < .001), week 5 (P < .001), week 6 (P < .001) in OE‐LINC00511 compared with OE‐control. Tumor weight was declined in OE‐LINC00511 than OE‐control (P < .001).
Conclusions
LINC00511 acts as a potential biomarker and therapeutic option for osteosarcoma.]]></abstract><cop>United States</cop><pub>John Wiley & Sons, Inc</pub><pmid>31893577</pmid><doi>10.1002/jcla.23164</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0003-2039-2948</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0887-8013 |
| ispartof | Journal of clinical laboratory analysis, 2020-05, Vol.34 (5), p.e23164-n/a |
| issn | 0887-8013 1098-2825 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7246352 |
| source | MEDLINE; Wiley Online Library Open Access; DOAJ Directory of Open Access Journals; Wiley Online Library Journals Frontfile Complete; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Adolescent Adult Animals Apoptosis Apoptosis - genetics Biopsy Bone cancer Bone Neoplasms - genetics Bone Neoplasms - mortality Bone Neoplasms - pathology Bone Neoplasms - therapy Cell Line, Tumor Cell migration Cell motility Cell proliferation cell survival Chemotherapy Child Female Gene Expression Regulation, Neoplastic Hospitals Humans Kaplan-Meier Estimate long intergenic non‐coding RNA 511 Male Medical prognosis Metastasis Mice, Inbred BALB C Neoadjuvant Therapy Non-coding RNA Osteosarcoma Osteosarcoma - genetics Osteosarcoma - mortality Osteosarcoma - pathology Osteosarcoma - therapy Prognosis Ribonucleic acid RNA RNA, Long Noncoding - genetics Sarcoma Surgery tumor progression Xenograft Model Antitumor Assays Xenografts Young Adult |
| title | Long intergenic non‐coding RNA 511 correlates with improved prognosis, and hinders osteosarcoma progression both in vitro and in vivo |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T13%3A12%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Long%20intergenic%20non%E2%80%90coding%20RNA%20511%20correlates%20with%20improved%20prognosis,%20and%20hinders%20osteosarcoma%20progression%20both%20in%20vitro%20and%20in%20vivo&rft.jtitle=Journal%20of%20clinical%20laboratory%20analysis&rft.au=Qiao,%20Suchi&rft.date=2020-05&rft.volume=34&rft.issue=5&rft.spage=e23164&rft.epage=n/a&rft.pages=e23164-n/a&rft.issn=0887-8013&rft.eissn=1098-2825&rft_id=info:doi/10.1002/jcla.23164&rft_dat=%3Cproquest_pubme%3E2332082187%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2406256112&rft_id=info:pmid/31893577&rfr_iscdi=true |